Exploring Biocon's approach to creating cheaper drugs through living organisms, their market share in supplying active pharmaceutical ingredients, their involvement in contract research, and the excitement surrounding Biocon Biologics.
A couple of days ago, Biocon announced that it had finally finished integrating Viatris’ business with itself. And since this was probably Biocon’s biggest acquisition till date, in today’s episode for 9th September 2023, we thought it’d be a good time to see what this biopharmaceutical company has been up to.
Watch our latest YouTube - https://www.youtube.com/watch?v=FO_NA4DKLVQ